menu
    • menu

    Find Inclisiran manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 9
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    11

    API Suppliers

    API Suppliers

    2

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    1

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    6

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    4

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    2

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    9PROSPECTS

    39DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    10

    US Patents

    1

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 700,271

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    1,233

    Regulatory FDF Prices

    NA

    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    5

    API

    0

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    50

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736101800,"product":"INCLISIRAN INCLISIRAN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1302","totalValueFC":"130759.9","currency":"USD","unitRateINR":"112753.2","date":"06-Jan-2025","totalValueINR":"11275320","totalValueInUsd":"130759.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"7642182","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"ROOM 1101, BUILDING A, NO.58, TANZHU ROAD, SHANGHAI CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1737570600,"product":"\\\"FOC\\\" INCLISIRAN SODIUM IMP\\'S (AS02-3-IM2 -AS02-6-IM28) (18BAGS=300 MG)\\\"FOC\\\" INCLISIRAN SODIUM IMP\\'S (AS02-3-IM2 -AS02-6-IM28) (18","address":"564\/A\/22, ROAD NO.92","city":"HYDERABAD,ANDHRA PRADESH","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"MYLAN LABORATORIES LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.3","unit":"GMS","unitRateFc":"20","totalValueFC":"6.1","currency":"USD","unitRateINR":"1742","date":"23-Jan-2025","totalValueINR":"522.6","totalValueInUsd":"6.1","indian_port":"Bangalore Air","hs_no":"29349990","bill_no":"7949796","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"No. 28, Jian an Road, High-Tech Ind ustrial Development Zone, Yangzhou City, Jiangsu Province 225100, P.R.","customerAddress":"564\/A\/22, ROAD NO.92"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747765800,"product":"INCLISIRAN SODIUM (LIST 4 SR.NO.148) INCLISIRAN SODIUM (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"680","totalValueFC":"344786.1","currency":"USD","unitRateINR":"58752","date":"21-May-2025","totalValueINR":"29376000","totalValueInUsd":"344786.1","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"2187525","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":", LTD.NO.28,JIANAN ROAD,HIGH-TECHIN DUSTRIAL DEVELOPMENT ZONE,YANGZHOUC ITY,JIANGSU PROVINCE 225100, P.R. CHINA","customerAddress":"MUMBAI CENTRAL,"}]
    06-Jan-2025
    21-May-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Early Hospital Initiation of Inclisiran Safety and Efficacy In ACS

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 04, 2025

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Early Hospital Initiation of Inclisiran Safety and Efficacy In ACS

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    August 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Novartis’ Leqvio For First-Line Twice-Yearly Use

    Details:

    Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2025

    blank

    02

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Approves Novartis’ Leqvio For First-Line Twice-Yearly Use

    Details : Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    July 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention o...

    Details:

    Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Inclisiran Sodium,Inclisiran

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 03, 2025

    blank

    03

    Duke University

    Country
    arrow
    VMX
    Not Confirmed

    Duke University

    Country
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran Sodium,Inclisiran

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Pa...

    Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

    Details:

    Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.


    Lead Product(s): Inclisiran Sodium,Inclisiran

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 10, 2025

    blank

    04

    University of California, San Diego

    Country
    arrow
    VMX
    Not Confirmed

    University of California, San Diego

    Country
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran Sodium,Inclisiran

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

    Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    March 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

    Details:

    Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.


    Lead Product(s): Pelacarsen,Inclisiran

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 07, 2025

    blank

    05

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pelacarsen,Inclisiran

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevat...

    Details : Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    February 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 19, 2024

    blank

    06

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Fami...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 19, 2024

    blank

    07

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hyperch...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis' Leqvio® Shows Significant LDL-C Lowering As Monotherapy

    Details:

    Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 28, 2024

    blank

    08

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis' Leqvio® Shows Significant LDL-C Lowering As Monotherapy

    Details : Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    August 28, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

    Details:

    Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 09, 2024

    blank

    09

    EnPlusOne Biosciences

    U.S.A
    arrow
    VMX
    Not Confirmed

    EnPlusOne Biosciences

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

    Details : Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    July 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemi...

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 26, 2024

    blank

    10

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients ...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    india-flag.png
    Inclisiran API needed in India [ENA24034]
    A company that focuses on the manufacturing of various finished formulations is looking for suppliers of Inclisiran API for development purposes. The suppliers must support this enquiry with DMF & CoA.
    15 Sep 2025

    Reply

    15 Sep 2025

    Reply text-arrow

    Reply Comment (2)

    15 Sep 2025

    india-flag.png
    Injectable Grade Inclisiran API needed in India [ENA23425]
    A company that focuses on the development and manufacturing of OSDs, liquids, semi-solids and injectables is looking for suppliers of Injectable Grade Inclisiran API. The initial required quantity is 500 g for development & exhibit batches, later 1 kg - 2 kg for commercial purposes. The suppliers must support this enquiry with CoA.
    04 Jul 2025

    Reply

    04 Jul 2025

    Reply text-arrow

    Reply Comment (1)

    04 Jul 2025

    Oman.png
    Inclisiran (1 g) API needed in Oman [ENA20652]
    A company that focuses on development of various vaccine and medicine in areas of oncology, immunology and gene therapy is looking for suppliers of Inclisiran (1 g) API for development purposes. The suppliers must support this enquiry with GMP & CoA.
    25 Sep 2024

    Reply

    25 Sep 2024

    Reply text-arrow

    Reply Comment (5)

    25 Sep 2024

    india-flag.png
    Inclisiran Sodium API needed in India [ENA18923]
    A company that focuses in research, development and manufacturing of complex generic and novel innovative pharmaceutical products such as oral solid dosage forms, injectables and nutraceuticals is looking for suppliers of Inclisiran Sodium API for development purposes. The required quantity is MOQ. The suppliers must support this enquiry with CoA.
    18 Jan 2024

    Reply

    18 Jan 2024

    Reply text-arrow

    Reply Comment (3)

    18 Jan 2024

    Egypt.png
    Inclisiran (200 g) API needed in Egypt [ENA16468]
    A company that deals in various pharmaceutical products is looking for suppliers of Inclisiran (200 g) API for development purposes. The suppliers must support this enquiry with CoA.
    24 Feb 2023

    Reply

    24 Feb 2023

    Reply text-arrow

    Reply Comment (8)

    24 Feb 2023

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2034-08-18

    INCLISIRAN SODIUM

    US Patent Number : 12460206

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-08-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2028-08-24

    INCLISIRAN SODIUM

    US Patent Number : 10131907

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-08-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2028-12-04

    INCLISIRAN SODIUM

    US Patent Number : 9370582

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2028-12-04

    INCLISIRAN SODIUM

    US Patent Number : 8828956

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2027-05-10

    INCLISIRAN SODIUM

    US Patent Number : 8809292

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-05-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2027-12-29

    INCLISIRAN SODIUM

    US Patent Number : 8222222

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-12-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2029-12-12

    INCLISIRAN SODIUM

    US Patent Number : 8106022

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2029-12-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2034-08-18

    INCLISIRAN SODIUM

    US Patent Number : 10125369

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-08-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2028-12-04

    INCLISIRAN SODIUM

    US Patent Number : 10806791

    Drug Substance Claim : Y

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    VMX
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    VMX
    Not Confirmed

    Patent Expiration Date : 2036-08-25

    INCLISIRAN SODIUM

    US Patent Number : 10851377

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-08-25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search